ceftaroline + vancomycin

Ceftaroline + vancomycin is a combination of two intravenous antibiotics used primarily as salvage therapy for persistent or complicated methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Ceftaroline is a fifth-generation cephalosporin with activity against MRSA, acting by binding to penicillin-binding proteins and inhibiting bacterial cell wall synthesis. Vancomycin is a glycopeptide antibiotic that inhibits cell wall biosynthesis in Gram-positive bacteria by binding to D-alanyl-D-alanine termini of cell wall precursors, preventing peptidoglycan polymerization. The combination has been explored for synergy in cases where monotherapy fails, particularly in severe or persistent MRSA infections. While some studies suggest rapid clearance of bacteremia and high microbiological cure rates with this regimen, clinical outcomes such as mortality and recurrence are not consistently superior to monotherapy. Both drugs are administered intravenously and require monitoring for adverse effects such as nephrotoxicity (vancomycin) and rash or neutropenia (ceftaroline).